STRATEC Biomedical AG (DE:SBS)
XETRA:SBS
Want to see DE:SBS full AI Analyst Report?
Top Page
STRATEC Biomedical
(XETRA:SBS)
Select Model
Select Model
Rating:47Neutral
Price Target:
€17.50
▼(-21.87% Downside)
Action:ReiteratedDate:05/01/26
The score is held down primarily by deteriorating fundamentals—multi-year revenue decline, margin compression, and especially the sharp reversal to negative 2025 cash flow. Technicals also remain bearish with price below key moving averages and negative MACD. Offsetting factors are a relatively supportive balance sheet and a mixed-but-stabilizing earnings outlook, including liquidity flexibility from the €125m loan and a moderate dividend yield.
Positive Factors
OEM/ODM recurring production model
STRATEC’s core OEM/ODM business yields recurring series-production revenue and multi-year development contracts. That model creates durable revenue runways once platforms commercialize, plus aftermarket and consumable opportunities that support predictable volume-based cash generation over several years.
Negative Factors
Multi-year revenue decline
Sustained top-line contraction across several years indicates weakening end-market demand or lost share with OEM partners. Continued revenue erosion undermines operating leverage, reduces scale benefits, and constrains reinvestment for R&D and capacity — a structural headwind to recovery over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
OEM/ODM recurring production model
STRATEC’s core OEM/ODM business yields recurring series-production revenue and multi-year development contracts. That model creates durable revenue runways once platforms commercialize, plus aftermarket and consumable opportunities that support predictable volume-based cash generation over several years.
Read all positive factors
STRATEC Biomedical (SBS) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€213.94M
Dividend Yield2.71%
Average Volume (3M)15.55K
Price to Earnings (P/E)―
Beta (1Y)1.46
Revenue GrowthN/A
EPS GrowthN/A
CountryDE
Employees1,462
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding12,157,841
10 Day Avg. Volume11,323
30 Day Avg. Volume15,548
Financial Highlights & Ratios
PEG Ratio11.11
Price to Book (P/B)1.15
Price to Sales (P/S)1.09
P/FCF Ratio-28.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€30.00Price Target Upside33.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.58
Revenue Forecast (FY)€270.85M
STRATEC Biomedical Business Overview & Revenue Model
Company Description
STRATEC Biomedical (SBS) is a leading provider of automation and instrumentation solutions for the medical technology and diagnostics industries. The company specializes in the development and production of complex systems used in laboratories and...
How the Company Makes Money
STRATEC Biomedical makes money mainly by designing, industrializing, and producing automated diagnostic and laboratory instrumentation for other companies under long-term OEM/ODM relationships. Key revenue streams typically include: (1) Developmen...
STRATEC Biomedical Earnings Call Summary
Earnings Call Date:Nov 07, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 11, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mixed outlook with both achievements and challenges. While there were positive developments in sales growth, partnership expansion, and financial optimization, significant challenges were faced due to supply chain disruptions, margin declines, and decreased net income.Positive Updates
New CFO Appointment
Tanja Bucherl has been appointed as the new CFO, bringing a strong financial background and team spirit to the organization.
Negative Updates
Supply Chain Disruptions
Supply chain interruptions impacted sales, particularly in the immunoassay franchise, causing delivery shortfalls.
Read all updates
Q3-2025 Updates
Positive
Negative
New CFO Appointment
Tanja Bucherl has been appointed as the new CFO, bringing a strong financial background and team spirit to the organization.
Read all positive updates
Company Guidance
In the 2025 financial results call, Stratec provided guidance indicating a flat top-line expectation for the year, matching the previous year's figures on a constant currency basis. The company anticipates an adjusted EBIT margin between 10% and 12%, but expects to end towards the lower end of this range due to product mix and ongoing supply chain issues. Despite these challenges, Stratec confirmed a 2.5% sales increase at constant exchange rates, reaching EUR 175.6 million for the first nine months. The adjusted EBIT margin for this period was 7.3%, down from 8.8% the previous year, largely due to a decline in the gross margin from 27.4% to 25.8%. The company also anticipates a notable improvement in earnings dynamics and a better tax rate in Q4, which should result in a full-year tax rate significantly below the previous 26.5%. Additionally, a successful closing of a EUR 125 million syndicated loan was highlighted, enhancing financial flexibility. The company remains focused on cost discipline, inventory management, and executing its development and partnership strategies to support future growth.STRATEC Biomedical Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
64
Positive
Cash Flow
33
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 250.86M | 257.62M | 270.41M | 274.63M | 287.33M |
| Gross Profit | 64.22M | 76.39M | 68.16M | 79.49M | 87.71M |
| EBITDA | 27.19M | 47.34M | 43.16M | 57.53M | 66.52M |
| Net Income | -242.00K | 16.02M | 15.37M | 29.22M | 39.96M |
Balance Sheet | |||||
| Total Assets | 443.38M | 445.06M | 466.58M | 397.50M | 368.52M |
| Cash, Cash Equivalents and Short-Term Investments | 23.06M | 48.73M | 34.22M | 24.07M | 48.72M |
| Total Debt | 132.13M | 130.53M | 141.37M | 87.15M | 85.30M |
| Total Liabilities | 206.06M | 202.53M | 233.25M | 172.32M | 162.77M |
| Stockholders Equity | 237.32M | 242.53M | 233.33M | 225.18M | 205.76M |
Cash Flow | |||||
| Free Cash Flow | -9.71M | 30.52M | 2.00M | -8.74M | 43.24M |
| Operating Cash Flow | -433.00K | 48.71M | 19.43M | 10.28M | 63.47M |
| Investing Cash Flow | -16.80M | -15.97M | -44.16M | -19.00M | -20.13M |
| Financing Cash Flow | -6.30M | -20.30M | 35.44M | -14.11M | -34.33M |
STRATEC Biomedical Technical Analysis
Positive
22.40
Price Trends
19.23
Positive
20.88
Negative
23.75
Negative
Market Momentum
-0.18
Negative
60.07
Neutral
67.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SBS, the sentiment is Positive. The current price of 22.4 is above the 20-day moving average (MA) of 18.08, above the 50-day MA of 19.23, and below the 200-day MA of 23.75, indicating a neutral trend. The MACD of -0.18 indicates Negative momentum. The RSI at 60.07 is Neutral, neither overbought nor oversold. The STOCH value of 67.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:SBS.
STRATEC Biomedical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | €954.88M | 19.58 | 20.78% | 1.11% | 5.45% | 46.45% | |
65 Neutral | €1.48B | 37.27 | 9.11% | 3.46% | 4.23% | 32.89% | |
57 Neutral | €38.92B | 27.87 | 11.65% | 2.13% | 2.76% | 6.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | €847.61M | -30.69 | 1.59% | 0.15% | 11.83% | -79.57% | |
47 Neutral | €213.94M | -1,127.69 | 6.55% | 2.71% | ― | ― |
* Healthcare Sector Average
DE:SBS
STRATEC Biomedical
17.60
-6.40
-26.67%
DE:DRW8
Draegerwerk AG & Co. KGaA
70.00
22.49
47.35%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
15.26
-4.78
-23.87%
DE:SIS
First Sensor
56.00
-1.51
-2.63%
DE:GXI
Gerresheimer
24.54
-36.36
-59.70%
DE:SHL
Siemens Healthineers AG
34.88
-11.97
-25.55%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.